Does Aspirin Prevent Cardiovascular Events in Patients with Diabetes?

No benefit was found in a randomized trial in Japan, but the study was underpowered, and the results are inconclusive.

Some current guidelines recommend the use of aspirin for prevention of cardiovascular events in patients with diabetes. However, this recommendation is controversial because data specific to this population are sparse. To determine the benefit of antiplatelet therapy in diabetic patients, investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) study randomly assigned more than 2500 patients with type 2 diabetes and no history of atherosclerotic disease to receive either daily low-dose aspirin (81 mg or 100 mg) or no aspirin unless specifically indicated.

A total of 154 cardiovascular events (sudden or cardiovascular death; nonfatal MI or new or unstable angina; cerebrovascular or hemorrhagic stro…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

Does Aspirin Prevent Cardiovascular Events in Patients with Diabetes?

Topics

Reviewing Author